These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26022561)

  • 1. New generation adjuvants--from empiricism to rational design.
    O'Hagan DT; Fox CB
    Vaccine; 2015 Jun; 33 Suppl 2():B14-20. PubMed ID: 26022561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The path forward.
    De Gregorio E
    Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development.
    Tom JK; Albin TJ; Manna S; Moser BA; Steinhardt RC; Esser-Kahn AP
    Trends Biotechnol; 2019 Apr; 37(4):373-388. PubMed ID: 30470547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are we entering a new age for human vaccine adjuvants?
    O'Hagan DT; Fox CB
    Expert Rev Vaccines; 2015 Jul; 14(7):909-11. PubMed ID: 25947042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
    Dowling DJ
    Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of small molecules as vaccine adjuvants.
    Wu TY; Singh M; Miller AT; De Gregorio E; Doro F; D'Oro U; Skibinski DA; Mbow ML; Bufali S; Herman AE; Cortez A; Li Y; Nayak BP; Tritto E; Filippi CM; Otten GR; Brito LA; Monaci E; Li C; Aprea S; Valentini S; Calabrό S; Laera D; Brunelli B; Caproni E; Malyala P; Panchal RG; Warren TK; Bavari S; O'Hagan DT; Cooke MP; Valiante NM
    Sci Transl Med; 2014 Nov; 6(263):263ra160. PubMed ID: 25411473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.
    Dalençon F
    Hum Vaccin Immunother; 2013 Sep; 9(9):2013-4. PubMed ID: 23938771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical and functional characterization of vaccine antigens and adjuvants.
    Dey AK; Malyala P; Singh M
    Expert Rev Vaccines; 2014 May; 13(5):671-85. PubMed ID: 24702271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern Vaccines/Adjuvants Formulation--Session 2 (Plenary II): May 15-17, 2013--Lausanne, Switzerland.
    Collin N
    Hum Vaccin Immunother; 2013 Sep; 9(9):2015-6. PubMed ID: 23966098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
    Chauhan N; Tiwari S; Iype T; Jain U
    Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
    Baldridge JR; Crane RT
    Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbohydrate-based vaccine adjuvants - discovery and development.
    Hu J; Qiu L; Wang X; Zou X; Lu M; Yin J
    Expert Opin Drug Discov; 2015 Oct; 10(10):1133-44. PubMed ID: 26372693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination adjuvants: the next generation of adjuvants?
    Mutwiri G; Gerdts V; van Drunen Littel-van den Hurk S; Auray G; Eng N; Garlapati S; Babiuk LA; Potter A
    Expert Rev Vaccines; 2011 Jan; 10(1):95-107. PubMed ID: 21162624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
    Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
    Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal adjuvants: Opportunities and challenges.
    Zeng L
    Hum Vaccin Immunother; 2016 Sep; 12(9):2456-8. PubMed ID: 27159278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic adjuvants for modern vaccine formulations.
    Vogel FR
    Ann N Y Acad Sci; 1995 May; 754():153-60. PubMed ID: 7625649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
    Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
    J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.
    Tupin E
    Hum Vaccin Immunother; 2013 Sep; 9(9):2009-12. PubMed ID: 23896583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One does not fit all: new adjuvants are needed and vaccine formulation is critical.
    Korsholm KS
    Expert Rev Vaccines; 2011 Jan; 10(1):45-8. PubMed ID: 21162619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.